Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Braidwell LP

Braidwell LP trimmed its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 17.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,118,961 shares of the company’s stock after selling 238,348 shares during the period. Keros Therapeutics accounts for about 1.6% of Braidwell LP’s holdings, making the stock its 22nd largest holding. Braidwell LP owned about 3.73% of Keros Therapeutics worth $44,490,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in KROS. Mirae Asset Global Investments Co. Ltd. boosted its stake in Keros Therapeutics by 3.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,898 shares of the company’s stock worth $513,000 after purchasing an additional 404 shares during the period. Swiss National Bank lifted its position in Keros Therapeutics by 4.8% in the third quarter. Swiss National Bank now owns 45,600 shares of the company’s stock valued at $1,454,000 after purchasing an additional 2,100 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 356.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock valued at $138,000 after buying an additional 2,702 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Keros Therapeutics by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 181,578 shares of the company’s stock worth $7,220,000 after purchasing an additional 4,625 shares in the last quarter. Finally, CHI Advisors LLC grew its stake in shares of Keros Therapeutics by 1.4% during the 3rd quarter. CHI Advisors LLC now owns 407,633 shares of the company’s stock worth $12,995,000 after purchasing an additional 5,515 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on KROS. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday, May 9th. Piper Sandler reaffirmed an “overweight” rating and set a $105.00 price objective on shares of Keros Therapeutics in a report on Wednesday, March 27th. William Blair reissued an “outperform” rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Wedbush reaffirmed an “outperform” rating and set a $86.00 price target on shares of Keros Therapeutics in a research note on Thursday, February 29th. Finally, Truist Financial reissued a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research note on Wednesday, March 13th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $86.00.

Keros Therapeutics Trading Down 2.0 %

Shares of NASDAQ KROS traded down $0.99 during trading on Tuesday, reaching $47.87. The company had a trading volume of 583,642 shares, compared to its average volume of 377,437. The stock has a market capitalization of $1.73 billion, a PE ratio of -9.30 and a beta of 1.25. The stock has a 50-day moving average price of $54.91 and a two-hundred day moving average price of $53.25. Keros Therapeutics, Inc. has a twelve month low of $27.02 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.12. The firm had revenue of $0.08 million for the quarter. The business’s revenue was down 97.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.26) EPS. On average, sell-side analysts predict that Keros Therapeutics, Inc. will post -4.97 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.